HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Roger L Albin Selected Research

Huntington Disease (Huntington's Disease)

1/2021Huntington's Disease Community Perspectives on Desired Characteristics of Disease Modifying Therapies.
1/2021Reply to: "Cell Therapy for Huntington's Disease: Learning from Failure".
9/2015Potential trade-offs in treatment of premanifest Huntington's disease.
11/2014Differential effects of delayed aging on phenotype and striatal pathology in a murine model of Huntington disease.
1/2013The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.
10/2010Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease.
10/2010Early autophagic response in a novel knock-in model of Huntington disease.
9/2010Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease.
3/2009In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease.
3/2009Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Roger L Albin Research Topics

Disease

49Parkinson Disease (Parkinson's Disease)
12/2023 - 07/2002
19Dementia (Dementias)
10/2023 - 06/2002
18Alzheimer Disease (Alzheimer's Disease)
12/2023 - 06/2002
15Cognitive Dysfunction
12/2023 - 04/2010
11Neurodegenerative Diseases (Neurodegenerative Disease)
01/2023 - 05/2004
10Huntington Disease (Huntington's Disease)
01/2021 - 03/2009
4Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome)
12/2022 - 04/2002
3Hypokinesia (Bradykinesia)
12/2023 - 05/2013
3Movement Disorders (Movement Disorder)
11/2022 - 12/2012
3Parkinsonian Disorders (Parkinsonism)
01/2019 - 06/2015
3Tourette Syndrome (Tourette's Syndrome)
01/2019 - 01/2006
2Disease Progression
01/2022 - 01/2013
2Frontotemporal Dementia (Semantic Dementia)
08/2021 - 08/2012
2Tremor (Tremors)
01/2021 - 05/2013
2REM Sleep Behavior Disorder
02/2015 - 04/2012
2Leukoaraiosis
12/2014 - 05/2013
2Ataxia (Dyssynergia)
11/2003 - 08/2003
1Amyloid Plaque
10/2023
1Hemorrhage
10/2023
1Ketosis
01/2023
1Multiple System Atrophy
11/2022
1Tics (Tic)
01/2019
1Late Onset Disorders
01/2018
1Orthostatic Hypotension (Postural Hypotension)
11/2016
1Proteostasis Deficiencies
10/2015
1Neurobehavioral Manifestations
10/2013
1Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
10/2012
1Corticobasal Degeneration
08/2012
1Sleep Apnea Syndromes (Sleep Apnea)
01/2012
1Leukoencephalopathies
08/2011
1Gliosis
10/2010
1Anosmia
06/2010
1Hepatolenticular Degeneration (Wilson's Disease)
03/2009
1Epilepsy (Aura)
09/2008

Drug/Important Bio-Agent (IBA)

27Cholinergic Agents (Cholinergics)IBA
09/2023 - 01/2002
12Amyloid (Amyloid Fibrils)IBA
10/2023 - 06/2011
12Proteins (Proteins, Gene)FDA Link
01/2019 - 11/2003
10Biomarkers (Surrogate Marker)IBA
12/2023 - 09/2006
10Dopamine (Intropin)FDA LinkGeneric
12/2023 - 01/2006
10polyglutamineIBA
01/2019 - 08/2003
10dihydrotetrabenazineIBA
12/2014 - 04/2010
7Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA
05/2013 - 06/2002
5Levodopa (L Dopa)FDA LinkGeneric
12/2023 - 05/2013
5AcetylcholinesteraseIBA
01/2022 - 06/2010
4Vesicular Acetylcholine Transport Proteins (Vesicular Acetylcholine Transporter)IBA
12/2022 - 07/2017
4PropionatesIBA
01/2022 - 06/2010
4LigandsIBA
01/2022 - 11/2003
3fluoroethoxy-benzovesamicolIBA
12/2022 - 01/2021
3Serotonin (5 Hydroxytryptamine)IBA
01/2018 - 01/2012
2Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
11/2022 - 12/2012
2Dopamine Agonists (Dopamine Agonist)IBA
01/2022 - 07/2002
2LipidsIBA
09/2019 - 01/2019
2Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA
01/2018 - 01/2013
2UbiquitinIBA
10/2015 - 01/2013
2RadiopharmaceuticalsIBA
02/2015 - 08/2014
22- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA
03/2013 - 12/2012
2Neurotransmitter Agents (Neurotransmitter)IBA
04/2012 - 08/2011
2Glucose (Dextrose)FDA LinkGeneric
06/2011 - 04/2010
2N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
10/2010 - 03/2009
2Huntingtin ProteinIBA
09/2010 - 03/2009
1lecanemabIBA
10/2023
1Sequestering AgentsIBA
10/2023
1Glucosylceramidase (Glucocerebrosidase)IBA
09/2023
1EnzymesIBA
09/2023
1ApolipoproteinsIBA
01/2023
1N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA
01/2022
1Acetylcholine (Acetylcholine Chloride)FDA Link
01/2022
12- tert- butyl- 4- chloro- 5- (6- (2- (2- fluoroethoxy)ethoxy)pyridin- 3- ylmethoxy)- 2H- pyridazin- 3- oneIBA
01/2022
1Retinaldehyde (Retinal)IBA
08/2021
1Cholinergic ReceptorsIBA
01/2021
1Cholinergic Antagonists (Anticholinergics)IBA
01/2021
1Carrier Proteins (Binding Protein)IBA
01/2019
1SDMIBA
01/2019
1ioflupaneIBA
01/2018
1Proteasome Endopeptidase Complex (Proteasome)IBA
10/2015
1MetalsIBA
02/2015
1Threonine (L-Threonine)FDA Link
02/2015
1Alanine (L-Alanine)FDA Link
02/2015
1Apolipoproteins E (ApoE)IBA
11/2014
1Lansoprazole (Prevacid)FDA LinkGeneric
08/2014
1ubiquitin isopeptidaseIBA
01/2013
1Ataxin-3IBA
01/2013
1Deubiquitinating EnzymesIBA
01/2013
1CarbonIBA
12/2012
1Adenosine Triphosphatases (ATPase)IBA
11/2012
1Glutamic Acid (Glutamate)FDA Link
11/2012
1P-2 (P 2)IBA
10/2012
1Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
08/2012
13- amino- 4- (2- dimethylaminomethylphenylsulfanyl)benzonitrileIBA
01/2012
1N-Methylaspartate (NMDA)IBA
10/2010
1Dopamine Receptors (Dopamine Receptor)IBA
10/2010
1CalciumIBA
09/2010
1CopperIBA
03/2009
1tetrathiomolybdate (ammonium tetrathiomolybdate)IBA
03/2009
1IonsIBA
03/2009

Therapy/Procedure

20Denervation
09/2023 - 07/2009
7Therapeutics
12/2023 - 11/2003
2Activities of Daily Living (ADL)
11/2016 - 09/2006
1Cell- and Tissue-Based Therapy (Cell Therapy)
01/2021
1Institutionalization (Institutionalized Persons)
07/2014